About Aperiam Bio
Aperiam Bio is a company based in United States founded in 2019. Aperiam Bio has raised $13 million across 2 funding rounds from investors including OMX Ventures, Civilization Ventures and Axial. Aperiam Bio offers products and services including Technical Reagents, Cosmetics Enzymes, and Pulmonary Biologics. Aperiam Bio operates in a competitive market with competitors including Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Ocelot Bio and PolyPeptide, among others.
- Headquarter United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$13 M (USD)
in 2 rounds
-
Latest Funding Round
$9 M (USD), Seed
Nov 29, 2023
-
Investors
OMX Ventures
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aperiam Bio
Aperiam Bio offers a comprehensive portfolio of products and services, including Technical Reagents, Cosmetics Enzymes, and Pulmonary Biologics.
Enables viable manufacturing of inaccessible proteins for partners.
Provides shelf-stable enzymes for new cosmetic actives applications.
Develops proteins that retain activity for medical nebulization uses.
People of Aperiam Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Aperiam Bio
Aperiam Bio has successfully raised a total of $13M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $9 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aperiam Bio
Aperiam Bio has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include OMX Ventures, Civilization Ventures and Axial.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in transformative biotech companies by OMX Ventures.
|
Locked | Locked | Locked | |
|
Venture capital is provided to health tech and biology innovations.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Aperiam Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aperiam Bio
Investment portfolio details for Aperiam Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aperiam Bio
Detailed financials for Aperiam Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aperiam Bio Comparisons
Peer comparison for Aperiam Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aperiam Bio
Aperiam Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Ocelot Bio and PolyPeptide, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Company specializing in development of Biosimilars
|
|
| Locked | Locked | Locked |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| Locked | Locked | Locked |
CDMO and analytical services for peptide development are provided.
|
|
| Locked | Locked | Locked |
Ocelot Bio is a CDMO specializing in peptide manufacturing services.
|
|
| Locked | Locked | Locked |
Proprietary, GMP-grade, and non-GMP peptides are manufactured by PolyPeptide Labs.
|
Detailed competitors of Aperiam Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aperiam Bio
Complete news archive for Aperiam Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aperiam Bio
Aperiam Bio was founded in 2019 and raised its 1st funding round 4 years after it was founded.
Aperiam Bio is headquartered in United States.
Aperiam Bio is a funded company, having raised a total of $13M across 2 funding rounds to date.
Aperiam Bio was founded in 2019 in the United States. Proteins for industrial and therapeutic uses are produced through biotechnology processes. Operations center on the development and manufacturing of these proteins for sector-specific needs. The company operates within the biotech industry, with a focus on protein-based solutions. Its online presence is maintained via aperiambio.com, supporting information on activities and contacts.
Aperiam Bio's top competitors include Enzene Biosciences, Hybio Pharmaceutical and PolyPeptide.
Aperiam Bio offers Technical Reagents, Cosmetics Enzymes, and Pulmonary Biologics.
Aperiam Bio has 4 investors. Key investors include OMX Ventures, Civilization Ventures, Axial, and KdT Ventures.